Angio-3 Peptide Oral Therapy for Retinal Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal angiogenic diseases, such as age-related macular degeneration, are limited by the discomfort of anti-VEGF injections and the development of resistance in some patients, necessitating alternative therapeutic options.
Innovation Solution
Administration of a pharmaceutically effective amount of a peptide with the sequence Thr Pro His Thr His Asn Arg Thr Pro Glu, or variants like Thr Pro His Thr His Gln Xaa Thr Pro Glu, via oral, intravenous, or intravitreal routes to treat retinal angiogenic diseases, particularly in patients non-responsive to anti-VEGF therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF therapy is administered, then retinal angiogenesis is inhibited, but patient comfort and convenience deteriorate due to repeated intravitreal injections
Solution Approach 1:
The patent replaces the mechanical injection method with an oral pharmaceutical composition. Instead of requiring intravitreal injection, the invention uses orally administered small molecule compounds or peptides that systemically inhibit angiogenesis, thereby eliminating injection-related discomfort while maintaining therapeutic efficacy
Solution Approach 2:
The patent introduces oral pharmaceutical compositions as an intermediary approach. Rather than directly injecting anti-angiogenic agents into the eye, the invention uses orally bioavailable compounds that travel through the bloodstream to reach the retina, providing an indirect but effective route of administration that improves patient comfort
2Ease of operation
If anti-VEGF therapy is administered, then retinal angiogenesis is inhibited, but treatment reliability deteriorates due to development of resistance in some patients
Solution Approach 1:
The patent changes the chemical parameters of anti-angiogenic agents by developing oral small molecule inhibitors and peptides with different molecular structures and mechanisms of action. This diversification of therapeutic parameters provides alternative pathways that bypass resistance mechanisms developed against conventional anti-VEGF therapies
Solution Approach 2:
The patent employs composite therapeutic strategies by combining multiple anti-angiogenic compounds with different mechanisms of action in oral formulations. This multi-component approach creates synergistic effects that overcome single-agent resistance, maintaining reliable treatment efficacy across diverse patient populations
3Reliability
If conventional anti-angiogenic therapies are used, then treatment is effective, but treatment duration and frequency increase due to repeated administrations
Solution Approach 1:
The patent achieves continuous anti-angiogenic action through orally administered compounds with extended half-lives. The small molecule inhibitors and peptides are designed to maintain sustained plasma and retinal concentrations, providing continuous therapeutic effect that reduces the frequency of administration compared to conventional therapies
Data Source
AI summary
This disclosure provides methods of a method of treating a retinal angiogenic in a subject comprising administering an effective amount of an Angio-3 peptide.